Competition Law and Laboratory Services Market Concentration

1. Introduction

Laboratory services constitute an important healthcare market encompassing clinical pathology, diagnostic testing, molecular testing, blood testing, histopathology, microbiology, genetic testing, and specialised laboratory analysis. Competition concerns arise when a small number of laboratories acquire substantial market shares through mergers, acquisitions, exclusive arrangements, vertical integration, or control over essential laboratory infrastructure.

Market concentration is particularly significant because laboratory markets often exhibit economies of scale, high fixed costs, extensive collection networks, courier infrastructure, accreditation requirements, specialised equipment, physician relationships, and large testing databases. These factors can make entry by smaller laboratories difficult.

Competition authorities therefore examine whether concentration may result in:

• higher prices for hospitals, physicians, insurers or patients;
• reduced quality or turnaround times;
• reduced choice of laboratories;
• foreclosure of smaller laboratories;
• exclusionary contracts with physicians or hospitals;
• loss of independent pathology capacity;
• higher barriers to entry;
• reduced innovation in diagnostic testing; and
• excessive bargaining power over healthcare purchasers.

The most directly relevant enforcement experience comes from the United States and United Kingdom, although the principles are broadly applicable to competition-law analysis elsewhere.

2. Meaning of Market Concentration in Laboratory Services

Market concentration refers to the extent to which laboratory-service sales or contracts are controlled by a limited number of firms.

A laboratory market may become concentrated through:

1. horizontal mergers between competing laboratories;
2. acquisition of hospital laboratories;
3. acquisition of independent pathology practices;
4. consolidation of diagnostic networks;
5. vertical integration with hospitals, insurers or physician groups;
6. exclusive referral arrangements;
7. acquisition of specialised testing facilities; and
8. control over laboratory information systems or diagnostic platforms.

Example

Suppose a regional market contains five laboratories:

If A acquires B, the combined firm would control 65% of the market. The transaction would therefore require careful examination of unilateral effects, entry barriers, buyer power and competitive alternatives.

3. Relevant Product Market

Competition authorities should not automatically treat every laboratory service as one market.

Potentially distinct markets include:

• routine clinical laboratory testing;
• specialised/esoteric testing;
• pathology;
• histopathology;
• molecular diagnostics;
• genetic testing;
• microbiology;
• oncology diagnostics;
• hospital laboratory services;
• physician-group laboratory services;
• reference laboratory services;
• clinical-trial laboratory services; and
• pharmaceutical/GMP laboratory testing.

The distinction is important because substitution may be limited.

For example, a hospital seeking highly specialised molecular testing may not regard a small routine pathology laboratory as an adequate substitute.

The European Commission has specifically recognised that diagnostic laboratory services and laboratory services associated with clinical development can constitute separate product markets.

4. Geographic Market

Laboratory markets may be either local/regional or wider, depending upon the type of testing.

Local characteristics

Routine clinical testing often requires:

• patient-service centres;
• specimen collection;
• rapid transportation;
• courier networks;
• rapid turnaround;
• proximity to physicians and hospitals.

Consequently, geographic competition can be highly localised.

The FTC's Quest/Unilab investigation treated Northern California as the relevant geographic market because physician groups required laboratory infrastructure sufficiently proximate to their operations.

Wider markets

Highly specialised laboratory testing may have a broader geographic market because specimens can be transported over long distances and testing may be centralised.

Thus, geographic-market analysis must consider:

• specimen transportation;
• turnaround requirements;
• patient-service-centre density;
• courier infrastructure;
• regulatory requirements;
• accreditation;
• hospital contracts; and
• technical specialisation.

5. Why Laboratory Markets Are Particularly Susceptible to Concentration

A. Economies of scale

Large laboratories can spread:

• equipment costs;
• laboratory information-system costs;
• accreditation costs;
• specialist staffing costs;
• courier costs; and
• administrative expenses

over a large testing volume.

This can make large laboratories more cost-efficient than small entrants.

The FTC specifically identified economies of scale and high fixed costs as important barriers in the LabCorp/Westcliff matter.

B. Patient-service-centre networks

Large laboratories may operate extensive networks of collection centres.

A new laboratory may therefore have to replicate:

• collection centres;
• transportation networks;
• laboratories;
• reporting systems;
• sales personnel; and
• relationships with physicians.

This creates substantial sunk costs.

C. Physician relationships

Laboratory services are frequently obtained through physicians or physician groups.

A laboratory that already has physician relationships may possess an important competitive advantage.

This is particularly significant in managed-care markets where laboratory contracts may cover large patient populations.

D. Network effects

A larger laboratory can process more tests and develop:

• broader testing menus;
• faster turnaround;
• integrated reporting;
• specialised expertise; and
• larger operational datasets.

These advantages can reinforce concentration.

6. Major Competition-Law Concerns

6.1 Horizontal Merger

The most obvious concern is the acquisition of one laboratory by another competing laboratory.

The authority may examine:

• combined market share;
• HHI;
• closeness of competition;
• internal documents;
• bidding data;
• physician switching;
• price effects;
• entry barriers;
• efficiencies; and
• buyer power.

6.2 Loss of a Maverick Competitor

A smaller laboratory may exert disproportionate competitive pressure despite having a relatively modest market share.

For example, a smaller laboratory may regularly offer lower prices when negotiating contracts with physician groups.

Its acquisition by a dominant laboratory can therefore eliminate an important competitive constraint.

The FTC made this type of concern central to its challenge to LabCorp's acquisition of Westcliff.

6.3 Coordinated Effects

If consolidation reduces the number of significant competitors from five to two or three, coordination may become easier.

Possible risks include:

• parallel pricing;
• allocation of physician groups;
• coordinated contract terms;
• reduced discounting;
• information exchange; and
• reduced competitive bidding.

6.4 Vertical Foreclosure

A laboratory may integrate with:

• hospitals;
• insurers;
• physician networks;
• diagnostic platforms; or
• laboratory information systems.

A vertically integrated firm could potentially restrict competitors' access to important customers or infrastructure.

6.5 Exclusive Arrangements

Exclusive laboratory contracts can prevent competing laboratories from obtaining sufficient volume to enter or expand.

Such arrangements should therefore be examined for:

• duration;
• market coverage;
• foreclosure percentage;
• justification;
• availability of alternatives; and
• effects on entry.

7. Important Case Laws and Enforcement Decisions

Case 1: FTC v. Quest Diagnostics Inc. / Unilab Corporation

Authority: U.S. Federal Trade Commission
Year: 2003

This is one of the most important laboratory-concentration cases.

Quest Diagnostics proposed to acquire Unilab. The FTC concluded that the transaction would substantially increase concentration in the market for clinical laboratory testing services provided to physician groups in Northern California.

The proposed transaction would have produced a combined share exceeding 70%, while the HHI would have risen to above 5,300 according to the FTC's analysis.

The FTC regarded Quest and Unilab as particularly close competitors.

Remedy

The parties were required to divest substantial assets to LabCorp, including:

• 46 patient-service centres;
• five rapid-response laboratories;
• physician-group contracts; and
• associated assets and customer information.

Principle

High concentration combined with close competition and substantial entry barriers can justify structural merger remedies.

Case 2: FTC v. Laboratory Corporation of America / Westcliff Medical Laboratories

Authority: FTC
Year: 2010–2011

LabCorp acquired Westcliff Medical Laboratories for approximately $57.5 million.

The FTC alleged that the acquisition would substantially reduce competition in Southern California clinical laboratory testing services supplied to physician groups.

According to the FTC complaint, LabCorp, Westcliff and Quest served most physician groups in the region and the acquisition would leave LabCorp and Quest controlling approximately 89% of the relevant market.

The FTC was particularly concerned that Westcliff was an aggressive competitor whose pricing constrained LabCorp and Quest.

Litigation development

A federal court declined to grant the FTC's requested preliminary relief, including finding issues with the FTC's proposed product and geographic-market definitions. The FTC subsequently withdrew its appeal and dismissed the administrative proceeding.

Principle

This case demonstrates an equally important point:

High concentration alone does not establish an antitrust violation.

Market definition, competitive effects, entry, efficiencies and evidentiary support remain critical.

Case 3: Basildon and Thurrock University Hospitals / Southend University Hospital / Integrated Pathology Partnerships

Authority: UK Competition and Markets Authority
Year: 2014

The transaction involved a joint venture concerning pathology services between hospital trusts and Integrated Pathology Partnerships.

The CMA considered whether the transaction could create a relevant merger situation and whether it could result in a substantial lessening of competition.

The transaction received Phase 1 clearance.

Significance

This case demonstrates that consolidation involving pathology services is not automatically unlawful.

Authorities may consider:

• existing competitive constraints;
• hospital procurement;
• alternative pathology providers;
• geographic scope;
• the structure of the joint venture; and
• whether the transaction actually creates a substantial lessening of competition.

Principle

A concentration must be assessed on its actual competitive effects rather than merely on the existence of consolidation.

Case 4: Transforming Pathology Partnership Joint Venture

Authority: UK Office of Fair Trading
Year: 2014

The OFT investigated a proposed pathology joint venture involving several NHS hospital trusts.

The investigation considered whether the arrangement created a relevant merger situation and whether it could result in a substantial lessening of competition.

The OFT ultimately concluded at Phase 1 that the transaction did not qualify as a relevant merger situation.

Significance

The case illustrates an important jurisdictional issue:

Before examining competitive effects, the authority must determine whether the transaction actually falls within the applicable merger-control jurisdiction.

Principle

Not every collaboration or joint venture between healthcare providers necessarily constitutes a reviewable concentration.

Case 5: PPD / Thermo Fisher Scientific

Authority: European Commission
Context: Laboratory and clinical-development services

This matter is important because it illustrates how competition authorities distinguish between different types of laboratory services.

The European Commission examined laboratory services associated with clinical development, distinguishing them from diagnostic laboratory services.

The Commission found that PPD's position in laboratory services for clinical development was relatively small, including a global share in the range of approximately 5–10% and an EEA-wide share of approximately 0–5% in the relevant assessment.

The Commission therefore concluded that PPD did not possess significant market power capable of creating the alleged customer-foreclosure problem.

Principle

Market concentration must be assessed within the correct product market; combining technologically related but commercially different laboratory services can distort the competitive analysis.

Case 6: Goldfinch Laboratory v. Iowa Pathology Associates

Court: U.S. Court of Appeals for the Eighth Circuit
Year: 2026

This recent case concerns competition in pathology services rather than a merger.

Four pathologists left an established laboratory and established Goldfinch Laboratory as a competing business.

Goldfinch alleged that the incumbent laboratories had monopoly power in Central Iowa and had used restrictive employment arrangements and other conduct to preserve their position. Goldfinch further alleged conduct directed at physician referrers after the new laboratory entered the market.

The Eighth Circuit affirmed dismissal of Goldfinch's complaint.

Significance

The case illustrates that laboratory-market concentration can raise monopolization and exclusionary-conduct questions, not merely merger questions.

Important issues include:

• monopoly power;
• entry by new laboratories;
• physician referral relationships;
• restrictive employment agreements;
• exclusionary conduct; and
• proof of anticompetitive effects.

Principle

A laboratory's market power must be distinguished from unlawful exclusionary conduct; competition law does not prohibit monopoly itself, but potentially unlawful methods of acquiring or maintaining monopoly power.

8. Comparison of the Major Cases

9. HHI and Laboratory Market Concentration

The Herfindahl-Hirschman Index (HHI) is particularly useful in laboratory merger analysis.

It is calculated as:

HHI = Σ (market share of each firm)²

For example:

• Firm A = 40%
• Firm B = 30%
• Firm C = 20%
• Firm D = 10%

HHI:

40² + 30² + 20² + 10² = 3,000

The Quest/Unilab investigation illustrates how an extremely concentrated laboratory market can attract substantial antitrust scrutiny; the FTC's analysis identified a post-merger HHI exceeding 5,300.

However, HHI should not be treated as conclusive. Authorities also examine closeness of competition, entry, buyer power, efficiencies and actual contracting behaviour.

10. Barriers to Entry

Laboratory markets can have unusually high entry barriers.

Infrastructure

New entrants may need:

• accredited laboratories;
• sophisticated diagnostic equipment;
• patient-service centres;
• refrigerated transportation;
• courier networks;
• laboratory information systems;
• qualified pathologists;
• technicians; and
• quality-control systems.

Regulatory barriers

Laboratories may need compliance with:

• licensing requirements;
• accreditation standards;
• professional requirements;
• biosafety rules;
• data-protection rules; and
• quality-control regulations.

Commercial barriers

Physician and hospital contracts can also make entry difficult.

An entrant may possess technical capacity but still lack sufficient patient volume to operate efficiently.

11. Buyer Power

Large hospitals, insurers and physician groups can sometimes exercise substantial countervailing bargaining power.

This can mitigate concentration concerns.

For example, if hospitals can:

• switch laboratories;
• conduct competitive tenders;
• self-supply testing;
• use multiple laboratories; or
• negotiate volume discounts,

a laboratory may have less ability to raise prices.

However, buyer power must be demonstrated rather than assumed.

12. Quality Competition

Laboratory competition is not limited to price.

Important dimensions include:

• accuracy;
• turnaround time;
• reliability;
• test menu;
• geographic accessibility;
• specimen collection;
• reporting technology;
• customer service;
• innovation; and
• specialised testing capability.

Therefore, a merger may be problematic even where direct price increases are difficult to demonstrate if it significantly reduces quality or service competition.

13. Innovation Concerns

Concentration can affect innovation in:

• molecular diagnostics;
• genetic testing;
• AI-assisted pathology;
• liquid biopsy;
• cancer diagnostics;
• infectious-disease testing;
• personalised medicine; and
• laboratory automation.

A dominant laboratory may have less incentive to invest in innovative testing if competitive pressure declines.

Conversely, large laboratories can argue that scale produces efficiencies enabling them to invest more heavily in advanced technology.

Competition authorities therefore have to examine verifiable efficiencies against possible loss of innovation competition.

14. Remedies for Excessive Concentration

A. Divestiture

The strongest structural remedy is divestiture of:

• laboratories;
• patient-service centres;
• physician contracts;
• testing equipment;
• employees;
• customer relationships; and
• associated infrastructure.

Quest/Unilab is the classic example.

B. Behavioural Remedies

Authorities may also impose:

• non-discrimination obligations;
• restrictions on exclusivity;
• access obligations;
• interoperability requirements;
• information-firewall requirements;
• limits on tying; and
• contractual safeguards.

C. Monitoring

Post-merger monitoring may be necessary to ensure that divested assets remain viable and that the purchaser can actually compete.

15. Application to India

In India, laboratory-market concentration can be examined principally under the Competition Act, 2002.

Relevant provisions include:

Section 3

Concerns agreements that cause or are likely to cause an appreciable adverse effect on competition.

Potential laboratory applications include:

• exclusive laboratory agreements;
• market allocation;
• referral restrictions;
• anti-competitive distribution arrangements; and
• coordination among competing diagnostic providers.

Section 4

Concerns abuse of dominant position.

Potential conduct could include:

• discriminatory access;
• unfair pricing;
• denial of market access;
• tying;
• exclusionary contracts; and
• leveraging dominance from one laboratory-related market into another.

Sections 5 and 6

These provisions govern combinations and merger control.

A large acquisition involving competing diagnostic laboratories may therefore require examination of:

• relevant geographic market;
• relevant product market;
• market shares;
• concentration;
• closeness of competition;
• entry barriers;
• countervailing buyer power;
• efficiencies; and
• potential foreclosure.

16. Special Competition Concerns in Modern Laboratory Markets

Modern laboratories increasingly operate as technology businesses as well as healthcare businesses.

Important emerging concerns include:

1. AI pathology

A dominant laboratory may control large datasets used to develop AI diagnostic systems.

2. Laboratory information systems

Control over laboratory software can make switching to competitors more difficult.

3. Diagnostic platforms

A laboratory could potentially bundle testing with proprietary digital platforms.

4. Genetic databases

Large datasets may create competitive advantages that smaller laboratories cannot easily reproduce.

5. Hospital integration

A laboratory owned by a hospital network may potentially disadvantage independent laboratories.

6. Insurance integration

A laboratory-insurer combination could create concerns regarding access to patients and reimbursement arrangements.

7. Exclusive physician arrangements

Exclusive referral arrangements may make it difficult for rival laboratories to obtain sufficient volume.

17. Overall Legal Framework

The competition-law analysis of laboratory-market concentration can therefore be expressed as:

Market definition

↓

Geographic market

↓

Market shares and HHI

↓

Closeness of competition

↓

Entry and expansion barriers

↓

Buyer power

↓

Unilateral effects

↓

Coordinated effects

↓

Vertical/foreclosure concerns

↓

Quality and innovation effects

↓

Efficiencies

↓

Remedies

18. Key Principles Emerging from the Case Law

At least six important principles emerge from the cases:

1. Laboratory mergers can create serious horizontal concentration concerns, particularly where two major competitors combine, as demonstrated by Quest/Unilab.
2. Market definition is decisive. LabCorp/Westcliff demonstrates that the precise product and geographic markets can materially affect the outcome.
3. Economies of scale can create substantial entry barriers. Laboratory infrastructure, collection centres and courier networks can make entry difficult.
4. Pathology joint ventures are not automatically anti-competitive. The UK pathology cases demonstrate the need for transaction-specific analysis.
5. Different laboratory services may constitute separate relevant markets. The European Commission's PPD analysis illustrates the importance of distinguishing diagnostic services from clinical-development laboratory services.
6. Laboratory competition includes exclusionary-conduct issues. Goldfinch demonstrates how restrictive employment arrangements and conduct directed at physician referrals can become relevant to monopolization analysis.
7. Structural remedies can preserve competition. The Quest/Unilab divestiture illustrates the use of assets, contracts and infrastructure to recreate an effective competitor.
8. Market concentration alone is not sufficient. Authorities must examine whether concentration is likely to produce an actual or probable reduction in competitive constraints.

19. Conclusion

Laboratory-services markets present distinctive competition-law problems because scale, infrastructure, physician relationships, specialised technology and regulatory requirements can reinforce market concentration.

The central competition question is not simply whether one laboratory possesses a large market share. Authorities must determine whether concentration has reduced the competitive constraints available to physicians, hospitals, insurers and ultimately patients.

The leading laboratory cases demonstrate several recurring themes: horizontal consolidation, high entry barriers, localised competition, physician-group contracting, loss of maverick competitors, vertical foreclosure, market-definition disputes and the importance of structural remedies.